Icos regulatory update

ICOS received two U.S. Patents - Nos. 5,532,152 and 5,525,487. The '152 patent covers recombinant human platelet-activating factor acetylhydrolase (rPAF-AH), an enzyme that degrades the pro-inflammatory mediator PAF. ICOS is conducting a Phase I trial of rPAF-AH in healthy volunteers. Potential indications include acute respiratory distress syndrome, asthma, acute pancreatitis, inflammatory bowel disease, solid organ transplant and necrotizing entercolitis. ...